$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2024 Q2 Form 10-Q Financial Statement

#000143774924016366 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.545M $2.138M $1.512M
YoY Change -17.34% 42.5% 2.42%
% of Gross Profit
Research & Development $5.584M $5.784M $8.476M
YoY Change -37.89% 10.48% 34.6%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $8.130M $7.922M $9.988M
YoY Change -32.65% 17.62% 28.49%
Operating Profit -$8.130M -$7.922M
YoY Change -32.65% 17.62%
Interest Expense $82.46K $3.487K $192.7K
YoY Change 546.29% -54.45% 53.16%
% of Operating Profit
Other Income/Expense, Net $277.1K $495.9K $66.76K
YoY Change -175.74% 264.66% -114.46%
Pretax Income -$7.853M -$7.426M -$9.729M
YoY Change -36.86% 12.53% 19.96%
Income Tax $7.385K $7.396K -$4.580K
% Of Pretax Income
Net Earnings -$7.860M -$7.400M -$9.724M
YoY Change -36.61% 12.12% 19.78%
Net Earnings / Revenue
Basic Earnings Per Share -$0.26 -$0.25
Diluted Earnings Per Share -$0.26 -$0.25 -$0.36
COMMON SHARES
Basic Shares Outstanding 27.92M 27.92M 22.65M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.178M $11.97M $23.37M
YoY Change -44.6% 6.38% 26.18%
Cash & Equivalents $6.178M $11.97M $23.37M
Short-Term Investments
Other Short-Term Assets $1.055M $1.523M $332.9K
YoY Change 52.77% -7.47% -17.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.233M $13.50M $23.70M
YoY Change -38.92% 4.61% 25.24%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $819.7K
YoY Change
Total Long-Term Assets $819.7K $0.00 $0.00
YoY Change 40985950.0% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $7.233M $13.50M $23.70M
Total Long-Term Assets $819.7K $0.00 $0.00
Total Assets $8.053M $13.50M $23.70M
YoY Change -32.0% 4.61% 25.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.693M $5.720M $3.849M
YoY Change 77.22% 99.98% 9.34%
Accrued Expenses $9.043M $8.440M $13.33M
YoY Change 42.69% 178.33% 428.9%
Deferred Revenue
YoY Change
Short-Term Debt $207.5K $332.0K $0.00
YoY Change -6.74% -50.26%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.94M $14.49M $17.18M
YoY Change 51.43% 120.91% 184.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $150.2K $350.5K $806.7K
YoY Change -85.16% -37.0% 42.16%
Total Long-Term Liabilities $150.2K $350.5K $806.7K
YoY Change -85.16% -37.0% 42.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.94M $14.49M $17.18M
Total Long-Term Liabilities $150.2K $350.5K $806.7K
Total Liabilities $14.09M $14.84M $17.98M
YoY Change 37.9% 108.56% 172.15%
SHAREHOLDERS EQUITY
Retained Earnings -$149.6M -$141.8M -$134.4M
YoY Change 35.75% 44.99% 47.37%
Common Stock $2.982K $2.792K $2.792K
YoY Change 31.66% 36.53% 36.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.042M -$1.346M $5.719M
YoY Change
Total Liabilities & Shareholders Equity $8.053M $13.50M $23.70M
YoY Change -32.0% 4.61% 25.24%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$7.860M -$7.400M -$9.724M
YoY Change -36.61% 12.12% 19.78%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$8.476M -$11.73M -$8.876M
YoY Change 59.41% 47.47% 89.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.681M $332.0K 27.27M
YoY Change -48.58% -51.68% 146837.5%
NET CHANGE
Cash From Operating Activities -8.476M -$11.73M -8.876M
Cash From Investing Activities
Cash From Financing Activities 2.681M $332.0K 27.27M
Net Change In Cash -5.795M -$11.39M 18.40M
YoY Change 5474.71% 56.85% -493.73%
FREE CASH FLOW
Cash From Operating Activities -$8.476M -$11.73M -$8.876M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29887325
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21833598
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5718716 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14491969 usd
CY2024Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
350478 usd
CY2024Q1 us-gaap Liabilities
Liabilities
14842447 usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-456177 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11126 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
488744 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1216117 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-659693 usd
CY2023Q1 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
761736 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7951397 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23367456 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18519856 usd
CY2024Q1 us-gaap Assets
Assets
13496630 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7426212 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6848711 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
495894 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
135988 usd
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Assets
Assets
23700388 usd
CY2024Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
332000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5720455 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3849108 usd
CY2024Q1 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
6845910 usd
CY2023Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
11966812 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1216237 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
958607 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
377367 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
400490 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17175017 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
806655 usd
CY2023Q4 us-gaap Liabilities
Liabilities
17981672 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2138241 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
7922106 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6984699 usd
CY2023Q4 us-gaap Liabilities
Liabilities
17981672 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27918560
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27918560
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7951397 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141800000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6900000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, accounting for research and development activities, assumptions used to calculate the fair value of stock-based compensation, assumptions used to calculate the fair value of warrant liabilities, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially, all the Company’s cash and cash equivalents are held in demand deposit form at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p>
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3000000 usd
CY2023 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y1M6D
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2024Q1 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
12078099 usd
CY2024Q1 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y9M18D
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3000000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140439247 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140070172 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141787856 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134354248 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1345817 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5718716 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13496630 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23700388 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5783865 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5484145 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2138241 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1500554 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
7922106 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6984699 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7922106 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6984699 usd
CY2024Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
456177 usd
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
11126 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
3487 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
7655 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
173098 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-129894 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14494 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7396 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2978 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
369075 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1345817 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8394246 usd
CY2023Q1 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
19593 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51527 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1613677 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7433608 usd
CY2024Q1 us-gaap Depreciation
Depreciation
0 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
369075 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
51527 usd
CY2024Q1 rvph Increase Decrease In Prepaid Clinical Study Costs
IncreaseDecreaseInPrepaidClinicalStudyCosts
701307 usd
CY2023Q1 rvph Increase Decrease In Prepaid Clinical Study Costs
IncreaseDecreaseInPrepaidClinicalStudyCosts
26035 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7922106 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6984699 usd
CY2024Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
456177 usd
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
11126 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
3487 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
7655 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
173098 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
147011 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14494 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7396 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2978 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7433608 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
369075 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1345817 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8394246 usd
CY2023Q1 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
19593 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51527 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1613677 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7433608 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2024Q1 us-gaap Depreciation
Depreciation
0 usd
CY2023Q1 us-gaap Depreciation
Depreciation
0 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
369075 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
51527 usd
CY2024Q1 rvph Increase Decrease In Prepaid Clinical Study Costs
IncreaseDecreaseInPrepaidClinicalStudyCosts
701307 usd
CY2023Q1 rvph Increase Decrease In Prepaid Clinical Study Costs
IncreaseDecreaseInPrepaidClinicalStudyCosts
26035 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1871347 usd
CY2024Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
415000 usd
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
CY2024Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
83000 usd
CY2023Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
19593 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
332000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
687093 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11393809 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7264304 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11973647 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11255552 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
657 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
2241 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
3487 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-4886395 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11725809 usd
CY2024Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
415000 usd
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
CY2024Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
83000 usd
CY2023Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
19593 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
332000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
687093 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11393809 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11973647 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11255552 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
657 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
2241 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
3487 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Reclassifications</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Certain amounts in the prior year’s consolidated financial statements, as of December 31, 2023 have been reclassified to conform to the current period's presentation. This involved disclosing separately, prepaid clinical trial costs from the prepaid expenses and other current assets balance, which were previously disclosed in the aggregate. This reclassification had no effect on the Company's loss from operations, net loss per share.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p>
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Reclassifications</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Certain amounts in the prior year’s consolidated financial statements, as of December 31, 2023 have been reclassified to conform to the current period's presentation. This involved disclosing separately, prepaid clinical trial costs from the prepaid expenses and other current assets balance, which were previously disclosed in the aggregate. This reclassification had no effect on the Company's loss from operations, net loss per share.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p>
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5484145 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6984699 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6984699 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2023Q1 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
761736 usd
CY2024Q1 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
12078099 usd
CY2024Q1 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y9M18D
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5484145 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6984699 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6984699 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6851689 usd
CY2023Q1 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
761736 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7951397 usd
CY2024Q1 rvph Working Capital
WorkingCapital
1000000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141800000 usd
CY2024Q1 us-gaap Cash
Cash
12000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6900000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, accounting for research and development activities, assumptions used to calculate the fair value of stock-based compensation, assumptions used to calculate the fair value of warrant liabilities, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially, all the Company’s cash and cash equivalents are held in demand deposit form at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141800000 usd
CY2024Q1 us-gaap Cash
Cash
12000000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7400000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6900000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, accounting for research and development activities, assumptions used to calculate the fair value of stock-based compensation, assumptions used to calculate the fair value of warrant liabilities, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially, all the Company’s cash and cash equivalents are held in demand deposit form at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p>
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27918560
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3000000 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22444443
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18473128
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2023Q4 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
29686123 usd
CY2023 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y1M6D
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22444443
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18473128
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2023Q4 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
29686123 usd
CY2023 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y1M6D
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2024Q1 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
12078099 usd
CY2024Q1 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y9M18D
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22444443
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18473128
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
25067643
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.03
CY2023Q4 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
29686123 usd
CY2023 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y1M6D
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2024Q1 rvph Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0
CY2024Q1 rvph Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
12078099 usd
CY2024Q1 rvph Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y9M18D
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3000000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
369075 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
11200 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
5000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
369075 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
11200 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
5000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
369075 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
11200 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
5000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
369075 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51527 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
11200 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
5000 usd

Files In Submission

Name View Source Status
0001437749-24-016366-index-headers.html Edgar Link pending
0001437749-24-016366-index.html Edgar Link pending
0001437749-24-016366.txt Edgar Link pending
0001437749-24-016366-xbrl.zip Edgar Link pending
ex_670004.htm Edgar Link pending
ex_670005.htm Edgar Link pending
ex_670006.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20240331.xsd Edgar Link pending
rvph20240331_10q.htm Edgar Link pending
rvph-20240331_lab.xml Edgar Link unprocessable
rvph-20240331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending
rvph20240331_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
rvph-20240331_cal.xml Edgar Link unprocessable
rvph-20240331_def.xml Edgar Link unprocessable